Anzeige
Mehr »
Login
Samstag, 20.07.2024 Börsentäglich über 12.000 News von 685 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40C39 | ISIN: US5049221055 | Ticker-Symbol: N6B
Tradegate
17.07.24
16:16 Uhr
200,00 Euro
+5,68
+2,92 %
Branche
Sonstige Technologie
Aktienmarkt
S&P 500
1-Jahres-Chart
LABCORP HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
LABCORP HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
191,50197,0009:31
193,68194,9419.07.
PR Newswire
98 Leser
Artikel bewerten:
(0)

Labcorp Announces New Strategic Service Offerings within Precision Oncology Portfolio

Labcorp® Tissue Complete, a comprehensive genomic profiling service, now available in Geneva and Shanghai to support global clinical trials

Company expands leadership in liquid biopsy comprehensive genomic profiling for solid tumors with the integration of OmniSeq® INSIGHT circulating tumor DNA

BURLINGTON, N.C., June 3, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced new strategic service offerings within its precision oncology portfolio. The enhancements strengthen Labcorp's leadership as a premier, single-source partner for biopharmaceutical companies in advancing cancer research and patient care both in the United States and globally.

"Labcorp's portfolio expansion enhances our integrated service offerings and empowers our partners with the support and solutions they need to advance their therapeutic development programs," said Shakti Ramkissoon, M.D., Ph.D., MBA, vice president, medical lead for oncology at Labcorp. "Combined, this can make a lasting difference in patients' lives and health outcomes."

Bringing global expertise to comprehensive genomic profiling
Labcorp Tissue Complete, which is powered by the FDA-cleared and CE-marked PGDx elio tissue complete assay, is a comprehensive genomic profiling (CGP) service for research and investigational use. The offering leverages the global reach of Labcorp's central laboratories, standardizing multi-site biomarker-directed patient testing. Labcorp's standardized approach reduces variability, which can result from different chemistries, workflows and data analysis pipelines.

This expansion will extend availability of the service through owned laboratories in Geneva and Shanghai to support research and investigational use in global clinical trials, streamlining access for patients to oncology clinical trials, broadening the patient population, and helping improve logistical efficiencies through Labcorp's global network.

Expanding OmniSeq INSIGHT for ctDNA
Labcorp also expands its leadership in liquid biopsy CGP for solid tumors by adding OmniSeq INSIGHT circulating tumor DNA (ctDNA) into its portfolio of CGP services. This new offering, complements OmniSeq INSIGHT by evaluating the same set of key biomarkers, enabling delivery of integrated and uniform genomic variants, tumor mutational burden (TMB) and microsatellite instability (MSI) detection from blood and tissue specimens to support exploratory and longitudinal biopharmaceutical studies.

To learn about Labcorp's oncology solutions, visit https://oncology.labcorp.com/biopharma-partners.

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA, and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com.

SOURCE Labcorp

© 2024 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.